Janet O’Neil

Pfizer (United States) — United States

Medicine · Health Sciences

9h-index466citations37works11.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Dementia and Cognitive Impairment Research(11), Neurogenetic and Muscular Disorders Research(5), Gastroesophageal reflux and treatments(4), Cardiomyopathy and Myosin Studies(4), Helicobacter pylori-related gastroenterology studies(3)

Publications37 total

Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3
Neurology·2024· 33 citedOpen Access
American National Standards Committee (ANSC) C63® Holds Summer Workshop in Phoenix
IEEE Electromagnetic Compatibility Magazine·2024
EMC+SIPI 2024: Youth Technical Program Harness the Power of the Sun!
IEEE Electromagnetic Compatibility Magazine·2024
Treatment Effects Among Patients with Type 2 and Type 3 SMA Directly Reported by Patients and Caregivers from the TOPAZ Clinical Trial (P2-8.010)
Neurology·2023· 1 cited
American National Standards Committee (ANSC) C63 ® Holds Summer Workshop in Grand Rapids
IEEE Electromagnetic Compatibility Magazine·2023Open Access
Apitegromab in Spinal Muscular Atrophy (SMA): An Analysis of Multiple Efficacy Endpoints in the TOPAZ Trial (P15-5.005)
Neurology·2022· 2 cited
A Randomized Trial of Radiotherapy vs. Trans-Oral Surgery for Treatment De-Escalation in HPV-Associated Oropharyngeal Squamous Cell Carcinoma (ORATOR2)
International Journal of Radiation Oncology*Biology*Physics·2021· 12 cited
Relationship of pharmacokinetics and pharmacodynamics to apitegromab efficacy in patients with later-onset spinal muscular atrophy (Types 2 and 3 SMA): Results from the TOPAZ study
Journal of the Neurological Sciences·2021
SMA - TREATMENT
Neuromuscular Disorders·2021· 1 cited
Adjudicating mild cognitive impairment due to Alzheimer’s disease as a novel endpoint event in the TOMMORROW prevention clinical trial
Research Square (Research Square)·2021· 1 citedOpen Access
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial
The Lancet Neurology·2021· 108 cited
IMS2020 Microwave Application Sessions and Panels
IEEE Microwave Magazine·2020Open Access
O4‐11‐02: DEFINING COGNITION IN PRE‐DEMENTIA CLINICAL TRIALS: BASELINE NEUROPSYCHOLOGICAL DATA FROM THE TOMMORROW STUDY
Alzheimer s & Dementia·2019
The TOMMORROW study: Design of an Alzheimer's disease delay‐of‐onset clinical trial
Alzheimer s & Dementia Translational Research & Clinical Interventions·2019· 41 citedOpen Access
P1‐050: ADJUDICATING MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE AS A NOVEL ENDPOINT EVENT IN THE TOMMORROW STUDY: A DELAY‐OF‐ONSET PHASE 3 CLINICAL TRIAL
Alzheimer s & Dementia·2018
EMC Society Board of Directors meeting
IEEE Electromagnetic Compatibility Magazine·2018
TOMMORROW neuropsychological battery: German language validation and normative study
Alzheimer s & Dementia Translational Research & Clinical Interventions·2018· 11 citedOpen Access
[P1–059]: APPROACHES TO SUBJECT RETENTION IN A PHASE 3 DELAY‐OF‐ONSET OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER's DISEASE (MCI‐AD) CLINICAL TRIAL: THE TOMMORROW STUDY EXPERIENCE
Alzheimer s & Dementia·2017
EMC society board of directors meeting
IEEE Electromagnetic Compatibility Magazine·2017
EMC society board of directors meeting
IEEE Electromagnetic Compatibility Magazine·2017
page 1 of 2Next →

Frequent Co-authors

Kathleen A. Welsh‐Bohmer(14), Carl Chiang(13), Daniel K. Burns(12), Brenda L. Plassman(11), Grant Runyan(9), Meredith Culp(8), Stephen Haneline(8), Ann M. Saunders(8), Heather Romero(7), Kathleen M. Hayden(7), Alexandra S. Atkins(7), Richard S.E. Keefe(7), Andreas U. Monsch(6), Shyama Brewster(6), Patrick J. Harrigan(5), Michael W. Lutz(5), Deborah Yarbrough(5), Craig A. Metz(5), D Barrett(5), Guochen Song(5)